LinkPeptide
![[Lys(Me2)9]-Histone H3 (1-21)-GGK(Biotin)-NH2](https://www.linkpeptide.com/wp-content/uploads/2026/05/LysMe29-Histone-H3-1-21-KBiotin.jpg "[Lys(Me2)9]-Histone H3 (1-21)-GGK(Biotin)-NH2")
![Smac/Diablo Peptide [AVPIAQKSE], 5-FAM labeled](https://www.linkpeptide.com/wp-content/uploads/2026/05/Smac-Diablo-Peptide-AVPIAQKSE-5-FAM-labeled.jpg "Smac/Diablo Peptide [AVPIAQKSE], 5-FAM labeled")
Get a Quote
Get a Quote
LinkPeptide provides high quality catalog peptides with different purity at highly competitive prices. Our catalog peptides are supported by our unparalleled experience in peptide synthesis. We have nearly 10 years experience in synthesizing peptides, LinkPeptide is the premier supplier of high quality peptides to leading biotechnology companies and academic institutions.
8
years of trusted peptide supply
Providing high-quality bioactive peptides, inhibitors, and custom peptide synthesis for pharmaceutical and academic research.
High-quality peptides for research, drug discovery, and cosmetic applications, 8+ years of peptide synthesis expertise,
End-to-end solutions from custom synthesis to large-scale production, flexible support for diverse research needs
8+ years of peptide synthesis expertise: Where proven quality meets advanced technologies for modern life science research.
LinkPeptide delivers high-quality catalog peptides with multiple purity options at competitive prices. Our products are backed by extensive experience in peptide synthesis and strict quality control standards.
With nearly a decade of expertise, LinkPeptide is a trusted partner for biotechnology companies and academic institutions, supporting research in drug discovery, molecular biology, and cosmetic science.
LinkPeptide provides high quality catalog peptides with different purity at highly competitive prices. Our catalog peptides are supported by our unparalleled experience in peptide synthesis. We have nearly 10 years experience in synthesizing peptides, LinkPeptide is the premier supplier of high quality peptides to leading biotechnology companies and academic institutions.
State-of-the-art production site supporting scalable peptide synthesis, from research-grade batches to large-scale manufacturing.
SPPS Synthesis Laboratory Equipped with advanced solid-phase peptide synthesis (SPPS) platforms, enabling precise, efficient, and high-throughput peptide productio
SPPS Synthesis Laboratory
Equipped with advanced solid-phase peptide synthesis (SPPS) platforms, enabling precise, efficient, and high-throughput peptide production.
Integrated Production Workflow
Seamless transition from synthesis to purification and analysis, ensuring fast turnaround and reproducible, high-quality peptide products.
HPLC & Mass Spectrometry
High-performance liquid chromatography (HPLC) and MS systems for purity analysis, identity confirmation, and batch consistency verification.
Targeted protein degradation (TPD) has revolutionized modern drug discovery, yet plasma membrane proteins—critical in cancer, immunity, and metabolism—have remained stubbornly difficult to degrade. Traditional PROTACs act only on intracellular targets, while lysosome-based systems like LYTACs depend on tissue-specific receptors and suffer from …
Details
AbstractAs the demand for peptide-based therapeutics grows, so too does the need for sustainable manufacturing methods. Traditional solid-phase peptide synthesis (SPPS), typically performed in the C-to-N direction, has long dominated the field—but it comes at a high environmental cost, consuming large amounts of reagents, solvents, and energy. …
Anticancer peptides (ACPs) are emerging as promising therapeutic agents in oncology, offering a safer and more targeted alternative to conventional cancer treatments. These small bioactive molecules demonstrate remarkable selectivity toward cancer cells, reducing off-target effects and toxicity. ACPs can be derived from natural sources, synthe…
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative modality in drug discovery by leveraging the ubiquitin–proteasome system to selectively degrade disease-associated proteins. While small-molecule PROTACs have demonstrated success, their reliance on well-defined ligandable pockets leaves many clinically relevant proteins …